EUVIMEDEUVIMED entdecken
Crossref

Dual‐Targeted Pt@Ce‐ MOF Nanoplatform Enhances Radiotherapy Efficacy via Tumor‐Specific Delivery and Mitochondrial Dysfunction in Breast Cancer

Yanyan Wang iD, Xinxin Han, Song Zhang, Lin Wang, Siyu Sun, Chun Xue, Tingjing Yao

Biopolymers · 2025

DOI: 10.1002/bip.70054 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biopolymers, 2025. Verfasst von Yanyan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Platinum, Mitochondria, Cerium. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Anhui Educational Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of multifunctional nanoplatforms capable of enhancing the efficacy and precision of cancer radiochemotherapy remains a significant clinical need. Here, we report a dual‐targeted cerium‐based metal–organic framework nanoplatform (Pt@Ce‐MOF‐RGD/FA) designed for synergistic radiosensitization and chemotherapeutic delivery in breast cancer. The Ce‐MOF core acts as a reactive oxygen species (ROS) amplifier under radiotherapy, while encapsulated cisplatin (Pt) serves as a chemotherapeutic agent. Surface modification with RGD and folic acid (FA) enables active targeting of tumor cells via αvβ3 integrin and folate receptor pathways. Comprehensive physicochemical characterization confirmed successful construction of the nanocomposite. In vitro, Pt@Ce‐MOF‐RGD/FA exhibited potent cytotoxicity, enhanced cellular uptake, inhibition of tumor cell migration, and robust ROS generation and mitochondrial membrane depolarization. In vivo fluorescence imaging demonstrated superior tumor accumulation of the dual‐ligand‐modified formulation. Under radiotherapy, Pt@Ce‐MOF‐RGD/FA achieved significant tumor growth suppression in a 4T1 murine breast cancer model without inducing systemic toxicity, as confirmed by blood biochemistry, hematological analysis, and histopathology. Collectively, this work presents a rationally engineered nanoplatform with precise tumor targeting, efficient drug delivery, and enhanced radiosensitization, offering a promising strategy for safe and effective cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsPlatinumMitochondriaCeriumMetal-Organic FrameworksCisplatinAntineoplastic AgentsAnimalsFemaleMiceHumansCell Line, TumorReactive Oxygen SpeciesFolic AcidMice, Inbred BALB COligopeptides

Stichwörter der Autor:innen

Ce‐MOFcisplatindual targetingnanomedicineradiochemotherapy

Substanzen

PlatinumCeriumMetal-Organic FrameworksReactive Oxygen SpeciesCisplatinAntineoplastic AgentsFolic Acidarginyl-glycyl-aspartic acidOligopeptides

Autor:innen und Institutionen

  • The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.

ORCID-Profile: Yanyan Wang

Förderung

  • Anhui Educational Committee

Zitieren

APA

Wang, Y., Han, X., Zhang, S., Wang, L., Sun, S., Xue, C., & Yao, T. (2025). Dual‐Targeted Pt@Ce‐ MOF Nanoplatform Enhances Radiotherapy Efficacy via Tumor‐Specific Delivery and Mitochondrial Dysfunction in Breast Cancer. Biopolymers. https://doi.org/10.1002/bip.70054

Vancouver

Wang Y, Han X, Zhang S, Wang L, Sun S, Xue C, et al. Dual‐Targeted Pt@Ce‐ MOF Nanoplatform Enhances Radiotherapy Efficacy via Tumor‐Specific Delivery and Mitochondrial Dysfunction in Breast Cancer. Biopolymers. 2025. doi:10.1002/bip.70054

BibTeX
@article{Wang2025,
  author = {Wang, Yanyan and Han, Xinxin and Zhang, Song and Wang, Lin and Sun, Siyu and Xue, Chun and Yao, Tingjing},
  title = {Dual‐Targeted Pt@Ce‐ MOF Nanoplatform Enhances Radiotherapy Efficacy via Tumor‐Specific Delivery and Mitochondrial Dysfunction in Breast Cancer},
  journal = {Biopolymers},
  year = {2025},
  doi = {10.1002/bip.70054}
}
Kostenlos starten →